-- Complement-targeted therapeutics have emerged as one of the fastest-growing areas in immunology drug development, with a surge of interest in treatments for autoimmune disorders, kidney diseases, neurological conditions, and rare diseases. However, accurately evaluating complement activation, pathway function, and therapeutic efficacy remains a major challenge for researchers seeking to advance promising drug candidates.
Researchers developing complement inhibitors and other complement-targeted therapies often face obstacles such as inconsistent assay performance, limited pathway-specific testing options, and difficulties correlating complement activity with therapeutic outcomes. These challenges can delay candidate selection and increase development costs.
To address these needs, Creative Biolabs has expanded its complement testing portfolio, providing researchers with specialized solutions for complement pathway analysis, complement inhibitor screening, and functional evaluation throughout the drug development process.
The company's capabilities include:
• Complement activation assays for the classical, alternative, and lectin pathways
• Complement component analysis, including C1q, C3, C4, and related biomarkers
• Complement function assays for therapeutic evaluation
• Complement inhibitor screening and pharmacodynamic studies
• Customized assay development tailored to specific research objectives
Among the featured solutions is the CH50 functional test kit, a hemolysis-based assay designed to quantitatively measure classical complement pathway activity. The kit supports serum and plasma samples from multiple species, providing researchers with a reliable tool for complement function assessment and therapeutic candidate screening.
Creative Biolabs also offers hemolysis assay for solutes services to evaluate the hemolytic potential and biocompatibility of compounds, biologics, and formulations. These studies help researchers identify potential safety concerns and better understand complement-mediated cellular responses during preclinical development.
"As more organizations invest in complement-targeted therapeutics, the demand for reliable functional assays continues to grow," said a spokesperson from Creative Biolabs. "Our goal is to provide researchers with actionable data that supports candidate selection, mechanism-of-action studies, and preclinical decision-making."
Researchers worldwide continue to utilize Creative Biolabs' expertise to accelerate complement research programs.
"We needed a reliable CH50 assay to compare multiple complement inhibitors. The assay reproducibility and technical support exceeded our expectations." — Immunology Scientist, U.S. Biotechnology Company
"The hemolysis data helped us identify formulation-related safety concerns before advancing to later-stage studies, saving significant development time." — Preclinical Research Director
Researchers interested in evaluating complement activation, complement inhibitor efficacy, or hemolytic activity can consult with Creative Biolabs specialists to discuss project-specific testing strategies. To learn more, please visit https://www.creative-biolabs.com/complement-therapeutics/.
About Creative Biolabs
Creative Biolabs is a biotechnology company with a strong focus on complement therapeutic research, offering specialized platforms and services that accelerate the discovery, characterization, and optimization of complement‑targeted drugs. The company provides integrated solutions spanning complement pathway analysis, inhibitor development, functional assays, and translational studies, enabling researchers to explore mechanisms of complement activation and advance next‑generation complement‑based therapeutics.
Contact Info:
Name: Candy Swift
Email: Send Email
Organization: Creative Biolabs
Address: 17 Ramsey Road, Shirley, NY 11967, USA
Phone: 6318306441
Website: https://www.creative-biolabs.com/complement-therapeutics/
Release ID: 89195685
Google
RSS